Inhaled immunotherapy for pulmonary metastases of renal cell cancer;Inhalative immuntherapie beim pulmonal metastasierten nierenzellkarzinom

Urologe - Ausgabe A

Volumn 43, Issue 4, 2004, Pages 457-461

  Lummen G ^a   Schenck, M ^a   Borgermann C ^a   Eisenhardt, A ^a   Vom Dorp, F ^a   Sperling, H ^a   Rubben H ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Inhalation therapy; Interferon ; Interleukin 2; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 2;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; MALE; QUALITY OF LIFE; QUESTIONNAIRE; TOXICITY; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

ADMINISTRATION, INHALATION; ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 2642554847     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-004-0538-1     Document Type: Article

References (21)

1. Atkins MB, Sparano J, Fisher RI et al. (1993) Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol 11: 661-670
2. Atzpodien J, Lopez-Hänninen E, Kirchner E et al. (1995) Multiinstitutional home-therapy trial of recombinant human Interleukin-2 and Interferon-α-2 in progressive metastatic RCC. J Clin Oncol 13: 497-501
3. Choudhury M, Efros M, Mittelman A (1993) Interferons and Interleukins in metastatic renal cell carcinoma. Urology 41: 67-72
4. Chow W-H, Devesa SS, Warren JL, Fraumeni JF (1999) Rising incidence of renal cell cancer in the United States. JAMA 281: 1628-1631
5. DeKernion JB, Sarna G, Figlin R, Lindner A, Smith RB (1983) The treatment of renal cell carcinoma with human leukocyte alpha-interferon. J Urol 130: 1063-1066
6. Dutcher JP, Fisher RI, Weiss G et al. (1997) Outpatient subcutaneous Interleukin-2 and Interferon-α for metastatic renal cell cancer: Five year follow-up of the Cytokine Working Group study. Cancer J Sci Am 3: 157-162
7. Heinzer H, Huland E, Aalamian M, Huland H (1999) Behandlung des pulmonal metastasierten Nierenzellkarzinoms mit inhalativem Interleukin-2. Urologe A 38: 466-473
8. Huland E, Huland H, Heinzer H (1992) Interleukin-2 by inhalation: Local therapy for metastatic renal-cell carcinoma. J Urol 147: 344-348
9. Huland E, Heinzer H, Huland H (1994) Inhaled interleukin-2 in combination with low-dose systemic Interleukin-2 and Interferon-α in patients with pulmunary metastatic renal cell carcinoma: effectiveness and toxicity of mainly local treatment. J Cancer Res Clin Oncol 120: 221-228
10. Huland E, Falk B, Huebner D, Huland H (1995) In vivo system to detect long-term continous release of bioactive Interleukin-2 by immunopharmacological depot preparations in nude mice with human tumors. J Cancer Res Clin Oncol 122: 285-290
11. Lissoni P, Barni S, Ardizoia A et al. (1993) A randomized study of low-dose Interleukin-2 plus Interferon-α first line therapy for metastatic RCC. Tumori 79: 397-400
12. Lorenz J, Wilhelm M, Kessler M et al. (1996) Phase I trial of inhaled natural interleukin-2 for treatment of pulmonary malignancy: toxicity, pharmacokinetics and biological effects. Clin Cancer Res 2: 1115-1122
13. Lümmen G, Goepel M, Möllhoff S, Hinke A, Otto T, Rübben H (1996) Phase II study of Interferon-γ versus interleukin-2 and Interferon-α-2b in metastatic renal cell carcinoma. J Urol 155: 455-458
14. Lümmen G, Sperling H, Bex A, Otto T, Rübben H (1998) Modern concepts in the therapy of urinary tract (kidney, ureter, bladder and prostate) tumours. Pharmacol Res 38: 151-164
15. Lümmen G, Brinkmann OA, Luboldt HJ, Hertle L, Rübben H (2001) Interferon-α, Interleukin-2 and 5-Fluorouroacil versus mistletoe lectin in metastatic renal cell carcinoma - Long-term results. Eur Urol 39: 121
16. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214
17. Negrier S, Escudier B, Lasset C et al. (1996) Recombinant human Interleukin-2, recombinant Interferon-α-2a, or both in metastatic renal cell carcinoma. N Engl J Med 338: 1272-1279
18. Pisani P, Parkin DM, Ferlay J (1993) Estimates of the worldwide mortality from eighteen major cancers in 1985: implications for prevention and projections of future burden. Int J Cancer 55: 891-903
19. Sandock DS, Seftel AD, Resnik MI (1995) A new protocol for the followup of renal cell carcinoma based on pathological stage. J Urol 154: 28-31
20. Vogelzang NJ, Lipton A, Figlin R (1993) Subcutaneous Interleukin-2 plus Interferon-α-2a in metastatic renal cancer: an outpatient multicenter trial. J Clin Oncol 11: 1809-1816
21. Wirth MP (1993) Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am 20: 283-295